Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT03474770
Registration number
NCT03474770
Ethics application status
Date submitted
12/03/2018
Date registered
23/03/2018
Date last updated
30/08/2022
Titles & IDs
Public title
BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures
Query!
Scientific title
Evaluation of Safety and Efficacy of BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures
Query!
Secondary ID [1]
0
0
BNI-02-1b
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
FIAS
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Focal Impaired Awareness Seizures
0
0
Query!
Condition category
Condition code
Neurological
0
0
0
0
Query!
Epilepsy
Query!
Neurological
0
0
0
0
Query!
Other neurological disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - BIS-001ER
Experimental: BIS-001ER - Dose administration for each participant will begin at 0.25mg b.i.d. escalating sequentially every 4 days to a maximum tolerated dose or target dose of 1.75mg b.i.d. Upon reaching the target dose or maximum tolerated dose, participants will maintain that dose for the balance of the 1 month out-patient titration period, after which they will begin a 96-hour in-patient video EEG monitoring treatment period.
Treatment: Drugs: BIS-001ER
BIS-001 ER is an extended release formulation of the nutritional supplement Huperzine A.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Effect of BIS-001ER on Seizure Count
Query!
Assessment method [1]
0
0
Reduction in average daily seizure count between baseline (pre-treatment) and evaluation (on treatment) video EEG monitoring periods.
Query!
Timepoint [1]
0
0
6 Weeks
Query!
Secondary outcome [1]
0
0
Effect of BIS-001ER on Percent Reduction in Daily Seizure Count
Query!
Assessment method [1]
0
0
Percent reduction in average daily seizure count from the baseline VEM period compared to the evaluation video EEG monitoring period (on treatment).
Query!
Timepoint [1]
0
0
6 Weeks
Query!
Secondary outcome [2]
0
0
Effect of BIS-001ER on Seizure Count vs Titration Period (Diary)
Query!
Assessment method [2]
0
0
Percent reduction in average number of seizures from the baseline period. (screening/retrospective diary) compared to the last week of the titration treatment period.
Query!
Timepoint [2]
0
0
6 Weeks
Query!
Secondary outcome [3]
0
0
Percent of Treatment Responders
Query!
Assessment method [3]
0
0
Percent of participants considered treatment responders defined as those with a =25%, =50%, =75% reduction in seizures from the baseline VEM period compared to the VEM treatment evaluation period.
Query!
Timepoint [3]
0
0
6 Weeks
Query!
Secondary outcome [4]
0
0
Effect of BIS-001ER on Seizure Count During Extension Phase
Query!
Assessment method [4]
0
0
Percent reduction of average number of seizures vs. baseline/retrospective diary at 1, 3, 6, 12 months during the extension period.
Query!
Timepoint [4]
0
0
12 Months
Query!
Secondary outcome [5]
0
0
Complete Seizure Protection
Query!
Assessment method [5]
0
0
Proportion of subjects with 100% seizure reduction.
Query!
Timepoint [5]
0
0
6 Weeks
Query!
Secondary outcome [6]
0
0
Need for Rescue Medication
Query!
Assessment method [6]
0
0
Proportion of subjects requiring rescue medication at different dosages.
Query!
Timepoint [6]
0
0
6 Weeks
Query!
Eligibility
Key inclusion criteria
* Speak English with sufficient proficiency to read and comprehend the Informed Consent document, and to communicate with study staff.
* Be able to consent to participate by signing the Informed Consent document after a full explanation of the nature and purpose of this study.
* Have signed the Informed Consent before any study-specific procedures are performed.
* Be males or females between 18 - 65 years of age.
* Have a diagnosis of FIAS type epilepsy with or without additional focal aware or non-aware seizures with generalization.
* Have a current minimum average of 5 countable seizures / week to enroll in study.
* Have at least 5 focal impaired awareness seizures during the 96-hour baseline VEM period.
* Be receiving stable doses (for at least 4 weeks) of one to four currently marketed anti-epileptic drugs (AEDs), with or without vagus nerve stimulation (in which case the patient should be on the same stimulation parameters for at least 4 weeks).
* Have a negative urinary pregnancy test upon admission to the site on Day 1.
* Be in good general health in the judgment of the Principal Investigator based upon medical history, physical examination, standard 12-lead ECG, and clinical laboratory evaluations obtained within the two weeks prior to enrollment.
* Be able to comply with all study-specified procedures.
* Weight between 40 and 120 kg.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Has taken Huperzine A within the past year.
* Is planning to become pregnant or impregnate spouse, not using an acceptable method of birth control (defined as use of double-barrier birth control methods, use of oral contraceptives, or surgical sterilization), pregnant or nursing.
* Have non-epileptic events that could be confused by the patient and/or study staff as epileptic seizures.
* Has seizures that are difficult to count; for example, seizure clusters defined as multiple seizures with at least one seizure within 30 minutes of the previous seizure.
* Have less than the 5 minimum accepted seizures required during baseline evaluation period screen.
* Have a history of only seizure clusters, for example, seizure clusters defined as multiple seizures with at least one seizure within 30 minutes of the previous seizure.
* Has attempted suicide within the past 2 years.
* Has a history of status epilepticus in the 6 months previous to enrollment.
* Has a pre-existing medical condition (including an existing progressive or degenerative neurological disorder including brain tumor, active encephalitis, active meningitis or abscess) or takes medications that, in the Principal Investigator's opinion, could interfere with the participant's suitability for participation in the study.
* Has a history or evidence of significant psychiatric disturbance or illness, including alcohol or drug abuse within the past 2 years, or symptoms of psychosis (hallucinations, delusions) in the last 5 years.
* Has had any clinical laboratory abnormalities within the past two months, prior to screening, considered of clinical significance by the Principal Investigator.
* Is on concomitant therapy with non-AEDs that are cholinergic.
* Has participated in any clinical investigational drug or device study within four weeks prior to study entry.
* Inability to complete seizure diary.
* Is currently taking or has taken Epigallocatechin gallate (EGCG) within the past 14 days, or consume foods or drinks containing EGCG; including green, white, oolong teas and certain black teas, or food containing >100grams of carob powder within the past 14 days.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
NA
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
10/04/2018
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
30/12/2026
Query!
Actual
Query!
Sample size
Target
16
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
The Alfred Hospital - Melbourne
Query!
Recruitment hospital [2]
0
0
The Royal Melbourne Hospital - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
3050 - Melbourne
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Supernus Pharmaceuticals, Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to examine safety signals and demonstrate seizure reduction in adults with FIAS treated with BIS-001ER as an add-on therapy in an in-patient and out-patient study design.
Query!
Trial website
https://clinicaltrials.gov/study/NCT03474770
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Azmi Nasser, PhD
Query!
Address
0
0
Supernus Pharmaceuticals, Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT03474770
Download to PDF